Have a feature idea you'd love to see implemented?
Let us know!
DCTH Delcath Systems Inc
Price (delayed)
$9.85
Market cap
$314.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.2
Enterprise value
$309.7M
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is
Highlights
Delcath Systems's gross profit has soared by 101% from the previous quarter
The company's revenue has surged by 91% QoQ
Delcath Systems's equity has soared by 104% from the previous quarter but it has plunged by 65% YoY
DCTH's quick ratio has dropped by 67% year-on-year and by 49% since the previous quarter
Key stats
What are the main financial stats of DCTH
Market
Valuations
Earnings
Shares outstanding
31.97M
Market cap
$314.94M
Enterprise value
$309.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
32.18
Price to sales (P/S)
12.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.68
Revenue
$22.64M
EBIT
-$33.97M
EBITDA
-$33.76M
Free cash flow
-$26.2M
Per share
Balance sheet
Liquidity
EPS
-$1.2
Free cash flow per share
-$0.91
Book value per share
$0.31
Revenue per share
$0.79
TBVPS
$1.1
Total assets
$31.68M
Total liabilities
$23.11M
Debt
$3.07M
Equity
$8.57M
Working capital
$7.3M
Debt to equity
0.36
Current ratio
1.34
Quick ratio
0.97
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
-149.1%
Gross margin
81.3%
Net margin
-150.7%
Operating margin
-118.1%
Return on assets
-97.3%
Return on equity
-316.3%
Return on invested capital
-241.1%
Return on capital employed
-336.4%
Return on sales
-150%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DCTH stock price
How has the Delcath Systems stock price performed over time
Intraday
2.28%
1 week
6.72%
1 month
-10.86%
1 year
232.77%
YTD
136.78%
QTD
9.08%
Financial performance
How have Delcath Systems's revenue and profit performed over time
Revenue
$22.64M
Gross profit
$18.41M
Operating income
-$26.75M
Net income
-$34.12M
Gross margin
81.3%
Net margin
-150.7%
Delcath Systems's gross profit has soared by 101% from the previous quarter
DCTH's operating margin has surged by 93% year-on-year and by 61% since the previous quarter
Delcath Systems's net margin has surged by 93% YoY and by 68% QoQ
The company's revenue has surged by 91% QoQ
Growth
What is Delcath Systems's growth rate over time
Valuation
What is Delcath Systems stock price valuation
P/E
N/A
P/B
32.18
P/S
12.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.68
Delcath Systems's EPS has soared by 64% YoY and by 50% from the previous quarter
Delcath Systems's equity has soared by 104% from the previous quarter but it has plunged by 65% YoY
DCTH's P/B is 30% higher than its last 4 quarters average of 24.7
The company's revenue has surged by 91% QoQ
The price to sales (P/S) is 44% less than the last 4 quarters average of 22.5 and 43% less than the 5-year quarterly average of 22.0
Efficiency
How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 92% YoY and by 68% from the previous quarter
The ROE has soared by 90% year-on-year and by 17% since the previous quarter
The company's return on invested capital has surged by 75% YoY and by 41% QoQ
The ROA has increased by 37% YoY and by 33% QoQ
Dividends
What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DCTH.
Financial health
How did Delcath Systems financials performed over time
The total assets is 37% greater than the total liabilities
DCTH's quick ratio has dropped by 67% year-on-year and by 49% since the previous quarter
Delcath Systems's current ratio has plunged by 59% YoY and by 47% from the previous quarter
Delcath Systems's debt is 64% lower than its equity
Delcath Systems's equity has soared by 104% from the previous quarter but it has plunged by 65% YoY
DCTH's debt to equity has shrunk by 73% QoQ and by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.